title: Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
abstract: An important aspect of ocular herpes simplex virus type 1 (HSV-1) vaccine development is identification of an appropriate adjuvant capable of significantly reducing both virus replication in the eye and explant reactivation in trigeminal ganglia. We showed recently that a recombinant HSV-1 vaccine expressing interleukin-4 (IL-4) is more efficacious against ocular HSV-1 challenge than recombinant viruses expressing IL-2 or gamma interferon (IFN-gamma) (Y. Osorio and H. Ghiasi, J. Virol. 77:5774-5783, 2003). We have now constructed and compared recombinant HSV-1 viruses expressing IL-12p35 or IL-12p40 molecule with IL-4-expressing HSV-1 recombinant virus. BALB/c mice were immunized intraperitoneally with IL-12p35-, IL-12p40-, IL-12p35+IL-12p40-, or IL-4-expressing recombinant HSV-1 viruses. Controls included mice immunized with parental virus and mice immunized with the avirulent strain KOS. The efficacy of each vaccine in protecting against ocular challenge with HSV-1 was assessed in terms of survival, eye disease, virus replication in the eye, and explant reactivation. Neutralizing antibody titers, T-cell responses, and expression of 32 cytokines and chemokines were also evaluated. Mice immunized with recombinant HSV-1 expressing IL-12p35 exhibited the lowest virus replication in the eye, the most rapid virus clearance, and the lowest level of explant reactivation. The higher efficacy against ocular virus replication and explant reactivation correlated with higher neutralizing antibody titers, cytotoxic-T-lymphocyte activities, and IFN-gamma expression in recombinant HSV-1 expressing IL-12p35 compared to other vaccines. Mice immunized with both IL-12p35 and IL-12p40 had lower neutralizing antibody responses than mice immunized with IL-12p35 alone. Our results confirm that recombinant virus vaccines expressing cytokine genes can enhance the overall protection against infection, with the IL-12p35 vaccine being the most efficacious of those tested. Collectively, the results support the potential use of IL-12p35 as a vaccine adjuvant, without the toxicity-associated concerns of IL-12.
authors.affiliation: Center for Neurobiology and Vaccine Development, Cedars-Sinai Medical Center Burns and Allen Research Institute, D2024, 8700 Beverly Blvd., Los Angeles, CA 90048, USA.
authors.forename: Yanira
authors.initials: Y
authors.lastname: Osorio
authors.forename: Homayon
authors.initials: H
authors.lastname: Ghiasi
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018925:Chemokines / Q000032:analysis; D016207:Cytokines / Q000032:analysis; D004195:Disease Models, Animal; D005260:Female; D022301:Herpes Simplex Virus Vaccines / Q000276:immunology*; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D018664:Interleukin-12 / Q000235:genetics / Q000276:immunology*; D053765:Interleukin-12 Subunit p35; D053762:Interleukin-12 Subunit p40; D015847:Interleukin-4 / Q000235:genetics / Q000276:immunology; D016849:Keratitis, Herpetic / Q000276:immunology* / Q000517:prevention & control*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D021122:Protein Subunits / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D012668:Trigeminal Ganglion; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D010948:Viral Plaque Assay; D014779:Virus Replication
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D018925:Chemokines; D016207:Cytokines; D022301:Herpes Simplex Virus Vaccines; C508858:IL12A protein, human; D053765:Interleukin-12 Subunit p35; D053762:Interleukin-12 Subunit p40; D021122:Protein Subunits; D014614:Vaccines, Synthetic; D018664:Interleukin-12; D015847:Interleukin-4
references.citation: Eur J Immunol. 1993 Sep;23(9):2202-8
references.pmid: 8103745
references.citation: Eur J Immunol. 1993 Aug;23(8):1762-70
references.pmid: 8102100
references.citation: J Leukoc Biol. 1994 Feb;55(2):280-8
references.pmid: 7905508
references.citation: J Virol. 1994 Apr;68(4):2118-26
references.pmid: 8138996
references.citation: J Immunol. 1994 Mar 15;152(6):2729-35
references.pmid: 7511624
references.citation: J Virol. 1995 Jan;69(1):334-40
references.pmid: 7983727
references.citation: J Immunol. 1995 Jan 1;154(1):116-27
references.pmid: 7527811
references.citation: Ophthalmology. 1994 Dec;101(12):1871-82
references.pmid: 7997323
references.citation: Eur J Immunol. 1995 Jan;25(1):200-6
references.pmid: 7843232
references.citation: J Exp Med. 1995 Mar 1;181(3):901-14
references.pmid: 7869050
references.citation: J Immunol. 1996 Jan 1;156(1):246-55
references.pmid: 8598469
references.citation: Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9085-9
references.pmid: 8799158
references.citation: Ann N Y Acad Sci. 1996 Oct 31;795:1-12
references.pmid: 8958912
references.citation: Immunology. 1997 Jul;91(3):430-5
references.pmid: 9301533
references.citation: Blood. 1997 Oct 1;90(7):2541-8
references.pmid: 9326219
references.citation: Semin Immunol. 1997 Oct;9(5):285-91
references.pmid: 9327523
references.citation: Cancer Res. 1998 Feb 1;58(3):491-9
references.pmid: 9458095
references.citation: Adv Immunol. 1998;70:83-243
references.pmid: 9755338
references.citation: Immunology. 1998 Nov;95(3):352-9
references.pmid: 9824497
references.citation: J Virol. 1999 Jan;73(1):501-9
references.pmid: 9847356
references.citation: J Immunol. 1999 Mar 1;162(5):2912-21
references.pmid: 10072541
references.citation: Curr Top Microbiol Immunol. 1999;238:57-78
references.pmid: 10087650
references.citation: J Infect Dis. 1999 May;179(5):1086-93
references.pmid: 10191208
references.citation: J Immunol. 1999 May 1;162(9):5270-7
references.pmid: 10228002
references.citation: Virology. 1999 Jun 5;258(2):208-16
references.pmid: 10366558
references.citation: J Interferon Cytokine Res. 2000 Mar;20(3):311-9
references.pmid: 10762079
references.citation: Immunity. 2000 Nov;13(5):715-25
references.pmid: 11114383
references.citation: J Leukoc Biol. 2001 Jan;69(1):149-57
references.pmid: 11200059
references.citation: Cancer Gene Ther. 2001 Apr;8(4):269-77
references.pmid: 11393279
references.citation: J Immunol. 2001 Jun 15;166(12):7419-26
references.pmid: 11390494
references.citation: J Virol. 2001 Oct;75(19):9029-36
references.pmid: 11533166
references.citation: J Immunol. 2001 Dec 1;167(11):6097-104
references.pmid: 11714768
references.citation: J Virol. 2002 Jan;76(1):243-50
references.pmid: 11739689
references.citation: Eur J Immunol. 2002 Aug;32(8):2308-16
references.pmid: 12209644
references.citation: Virus Res. 2002 Dec;90(1-2):317-26
references.pmid: 12457985
references.citation: J Immunol. 2002 Dec 15;169(12):7104-10
references.pmid: 12471147
references.citation: Nat Rev Immunol. 2003 Feb;3(2):133-46
references.pmid: 12563297
references.citation: Nature. 2003 Feb 13;421(6924):744-8
references.pmid: 12610626
references.citation: J Virol. 2003 May;77(10):5774-83
references.pmid: 12719570
references.citation: J Virol. 2003 Jun;77(12):6692-9
references.pmid: 12767989
references.citation: Ocul Immunol Inflamm. 2002 Jun;10(2):105-16
references.pmid: 12778346
references.citation: Immunity. 2003 Nov;19(5):641-4
references.pmid: 14614851
references.citation: Invest Ophthalmol Vis Sci. 2004 Feb;45(2):506-14
references.pmid: 14744892
references.citation: J Exp Med. 2004 Apr 5;199(7):1011-6
references.pmid: 15051764
references.citation: Surv Ophthalmol. 1976 Sep-Oct;21(2):121-35
references.pmid: 988644
references.citation: J Immunol. 1983 Jul;131(1):282-7
references.pmid: 6190911
references.citation: Clin Dermatol. 1984 Apr-Jun;2(2):56-66
references.pmid: 6443690
references.citation: J Infect Dis. 1987 May;155(5):914-20
references.pmid: 3031173
references.citation: J Virol. 1987 May;61(5):1571-6
references.pmid: 2952807
references.citation: J Gen Virol. 1987 Jul;68 ( Pt 7):1909-19
references.pmid: 3037014
references.citation: Prog Med Virol. 1987;34:89-128
references.pmid: 2821579
references.citation: J Immunol. 1988 Jan 1;140(1):294-9
references.pmid: 2826591
references.citation: Hematol Oncol Clin North Am. 1989 Sep;3(3):441-52
references.pmid: 2698876
references.citation: Intervirology. 1990;31(2-4):159-65
references.pmid: 2373609
references.citation: J Exp Med. 1990 Aug 1;172(2):487-96
references.pmid: 2165127
references.citation: Science. 1990 Nov 30;250(4985):1262-6
references.pmid: 2173860
references.citation: Immunology. 1990 Nov;71(3):358-63
references.pmid: 2176641
references.citation: J Exp Med. 1991 Apr 1;173(4):869-79
references.pmid: 1672545
references.citation: Virology. 1991 May;182(1):287-97
references.pmid: 1850907
references.citation: J Exp Med. 1992 Nov 1;176(5):1387-98
references.pmid: 1357073
references.citation: Vaccine. 1993;11(6):629-36
references.pmid: 8391739
references.citation: J Immunol. 1994 Feb 1;152(3):1253-64
references.pmid: 7905500